Background: Data on outpatient quinolone use in Europe were collected from 25 countries within the ESAC project, funded by DG SANCO of the European Commission, using the WHO ATC/DDD methodology. Results: Total outpatient quinolone use in 2003 varied by a factor of 12 between the country with the highest (3.10 DID in Portugal) and lowest (0.25 DID in Denmark) quinolone use. The second-generation quinolones represented more than 50% of the quinolone use (mainly ciprofloxacin) except for Croatia, where the firstgeneration was used most (mainly norfloxacin). In 22 countries, the use of second and/or third-generation quinolones increased at the expense of the use of first-generation quinolones. The new so-called respiratory quinolones (levofloxacin and moxifloxacin) represented more than 10% of quinolone use in 12 countries, with extreme seasonal variation in all these countries except for one.
Introduction
This article reviews the geographical variation and temporal trends of quinolone use in 25 European countries between 1997 and 2003. In-depth analysis of quinolone use was performed according to a classification based on their pharmacokinetic and in vitro potency profiles, which determines the area of clinical use. Additional data are available on the ESAC website (www.ua. ac.be/ESAC).
Methods
The methods for collecting use data of systemic antibiotics were described in the introductory article of this series, 1 and elsewhere. Table 2 ). First-generation quinolones (mostly represented by norfloxacin) still represented 85% of the total quinolone use in Croatia, more than 40% in the Czech Republic, Sweden, France and Slovenia and more than 10% in all but six countries (Denmark, Iceland, Israel, Ireland, Norway and the UK) in 2003. Both pipemidic acid and nalidixic acid were used in seven countries, ranging from 0.001 in Germany to 0.25 DID in Italy and from 0.00002 in Italy to 0.04 DID in Ireland, respectively. Among the other representatives of the first-generation, cinoxacin was used mainly in Italy (1.7% of total quinolone use), flumequine in France (1.3%), oxolinic acid in the Czech Republic, Poland and Slovakia (<0.05%), piromidic acid in Italy and rosoxacin in Portugal (both <0.001%).
Second-generation quinolones were by far the most widely used in Europe and exceeded 50% (median 63%) of total quinolone use in all countries except Croatia. Ciprofloxacin itself accounted for 41% of total quinolone use in 25 countries and was the most used in 18 of them. Its use varied from 0.14 DID in Israel to 1.74 DID in Portugal. Ofloxacin was the most used quinolone in two countries (Israel and Slovakia), while its purified S-enantiomer, levofloxacin, was most used in Italy.
Among the third-generation quinolones, which have been just recently introduced in Europe, only gatifloxacin and moxifloxacin have been prescribed in Europe and their use was recorded in all but six countries in 2003 (the Czech Republic, Estonia, Iceland, the Netherlands, Norway and Slovakia). Moxifloxacin represented 99.5% of the third-generation quinolones in 2003, whereas gatifloxacin use was only recorded in Germany. Third-generation quinolones are prescribed most frequently in high antibiotic consuming countries, 2 as well as in Austria and Germany. Table 2 and Figure S1 (Online Supplementary data) provide the overview of the consumption trends in the participating countries between 1997 and 2003. Between the first and the last year of observation, quinolone use was increasing in 20 countries, especially in Luxembourg (1.15 DID) and Belgium (0.98 DID). Only Slovenia, the UK and the Netherlands showed a decreasing trend of quinolone use, particularly due to declining use of the first-generation quinolones. 1 The proportional use of the different quinolone generations showed more dramatic variations, i.e. absolute differences of 10% or more between 1997 and 2003, in more than half of the countries. The proportional use of first-generation quinolones decreased by more than 20% in six and by more than 10% in another seven countries. This decrease was mainly the result of a decrease in norfloxacin use, except in Poland, Slovenia, Spain, France and Luxembourg where it also resulted from decreasing use of pipemidic acid and for Finland where from 2000 onwards cinoxacin was no longer used. This decrease was matched by a similar increase either in third-generation quinolones in Austria, Belgium and Spain, or second-generation quinolones in the Czech Republic, Finland, Greece, Ireland, the Netherlands, Poland, Slovenia and Sweden. In France and Luxembourg, the use of both second-and third-generation quinolones increased. On the other hand, the use of third-generation quinolones increased in Germany at the expense of the second-generation quinolones. Figures S2 and S3 (Online Supplementary data) show the seasonal fluctuation of quinolone use in 21 European countries that provided quarterly data. In all countries but Germany, the mean of the quinolone use in the first and fourth quarter did not exceed by more than 20% the mean of the use in the second and third quarter. The high seasonal fluctuation in Germany is determined by the relatively frequent use of third-generation quinolones, whose use increased in winter quarters by 84%. Similar seasonal fluctuations of third-generation quinolones were observed in most countries and ranged from 60% in Portugal to 118% in Austria, among six countries using more than 0.1 DID of these quinolones. However, second-generation quinolones also showed an increase in use in winter months, and this increase was higher than 20% in the Czech Republic (mainly ofloxacin), Poland (mainly ciprofloxacin) and Italy (mainly levofloxacin). Finally, the seasonal fluctuation of first-generation use varied from -6% in Denmark (summer use was higher than winter for another five countries) to 14% in Estonia (mainly due to norfloxacin).
Discussion
This study describes a striking variation of outpatient quinolone (ATC J01M) use in Europe, suggesting inappropriate prescribing in many countries.
We propose a classification based on Ball's 5 description of their pharmacokinetic and in vitro potency profiles. The quinolone in vitro potency profiles have shifted these agents used predominantly for the treatment of urinary tract infections in the 1960s-70s (our first-generation quinolones), to a more systemic use in the 1980s-90s (our second-generation quinolones), and, in the current millennium, to the treatment of respiratory tract infections (our third-generation quinolones). Several compounds have not yet received an ATC code, and are therefore not included in Table 1 (e.g. sitafloxacin, tosufloxacin and garenoxacin). Other classifications have been proposed. 4, 6 Andersson and MacGowan 6 added a fourth group with quinolones widely used against a broad range of tissue-based infections (including temafloxacin, clinafloxacin and trovafloxacin). However, moxifloxacin and garenoxacin (both third-generation quinolones based on our classification) are as active as trovafloxacin against anaerobes and their clinical indication may expand beyond the respiratory tract. In the classification of Andersson and MacGowan, levofloxacin is included in both the second (widely used against tissue-based and urinary infections) and fourth (main use in respiratory tract infections) group. We included levofloxacin in the secondgeneration because it is the S-enantiomer of ofloxacin. 7 This illustrates the complexity of quinolone classification.
During the 1990s, the use of second-generation quinolones was increasing steadily at the expense of the first-generation in most countries. This trend has accelerated more recently, especially in the countries with the highest quinolone use in Europe, through the introduction of the newer so-called 'respiratory' agents, levofloxacin as well as moxifloxacin. The pattern of quinolone use, however, is determined by the DDD value given to a certain agent, which is well demonstrated by analysing the quinolone use pattern in 2003, applying two DDD values for levofloxacin. The WHO Collaboration Centre decided to increase the DDD of levofloxacin from 0.25 to 0.5 g in 2004 due to its increased use for the treatment of respiratory tract infections, for which higher doses are prescribed than for urinary tract infections. This adjustment of DDD resulted in a less pronounced increase in consumption expressed in DID in countries with higher consumption of levofloxacin, such as Italy and Belgium. DDD changes of an agent over time create a serious problem for analysing trends of use, because we noticed that some data providers are not able to adjust their use data retrospectively or were not reporting the DDD value they used for levofloxacin. We were surprised to observe seasonal variation, with winter peaks presumably for the treatment of respiratory tract infections, of so-called 'urinary' quinolones with wide activity against Gram-negatives but marginal activity against Gram-positives. 2 We suggest that a low seasonal fluctuation of the earlier quinolones, such as ciprofloxacin and ofloxacin, is a good marker of restrained use. Conversely, the new, so-called 'respiratory' quinolones (levofloxacin and moxifloxacin), which already represented more than 10% of quinolone use in 12 countries in 2003, showed extreme seasonal variation in all these countries except for one.
In conclusion, although quinolones do not represent the firstline therapy for most adult respiratory tract infections in Europe, 8, 9 in ESAC we observed a substantial change in the prescribing pattern of these agents. Excessive use of quinolones is associated with development of resistance, requires more resources and exposes patients to the additional risk of side effects. Individual countries should define their own range of acceptable use considering the limited indications of quinolones and their demographical and epidemiological characteristics.
